Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC26A4 | O43511 | 7/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630351 | 1.00 | SLC26A4 (0.67) | SLC26A4KMT2AMEN1POLBLMNA | |
| SCHEMBL29095817 | 0.90 | PTGS2 (0.60) | SLC26A4KMT2AMEN1POLBLMNA | |
| SCHEMBL24484904 | 0.86 | SLC26A4 (0.76) | SLC26A4KMT2AMEN1POLBLMNA | |
| SCHEMBL29629888 | 0.85 | SLC26A4 (0.65) | SLC26A4KMT2AMEN1POLBLMNA | |
| SCHEMBL24485002 | 0.85 | SLC26A4 (0.65) | SLC26A4KMT2AMEN1POLBLMNA | |
| SCHEMBL24485029 | 0.84 | SLC26A4 (0.59) | SLC26A4KMT2AMEN1POLBLMNA | |
| SCHEMBL29629853 | 0.84 | SLC26A4 (0.59) | SLC26A4KMT2AMEN1POLBLMNA | |
| SCHEMBL27090435 | 0.84 | SLC26A4 (0.72) | SLC26A4KMT2AMEN1POLBLMNA | |
| SCHEMBL29630231 | 0.83 | SLC26A4 (0.43) | SLC26A4KMT2AMEN1POLBLMNA | |
| SCHEMBL24484972 | 0.83 | SLC26A4 (0.71) | SLC26A4KMT2AMEN1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051949-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2024-02-15 | — | — | US | disclosed |
| CN-116745283-A | Heterocyclic derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022112352-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051949-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM6, TRPM2 | SLC26A4 628/4885KMT2A 3314/4885MEN1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.